8-K: Clene Inc. Secures $8 Million NIH Grant Funding for ALS Treatment Program

Clene Inc. has secured an additional $8 million in funding from the National Institutes of Health for the second year of its Expanded Access Program for ALS treatment.

Summary

• Clene Inc. has received an amendment to its subaward agreement with Columbia University, securing up to $8 million in funding for the second year of its Expanded Access Program (ACT-EAP) for CNM-Au8 treatment of amyotrophic lateral sclerosis (ALS).
• The funding covers the period from September 1, 2024, to August 31, 2025.
• This amendment is part of a larger four-year, $45.1 million grant from the NIH, awarded under the Accelerating Access to Critical Therapies for ALS Act.
• The program is a collaboration between Clene, Columbia University, and Synapticure.

Sentiment

Score: 8

Explanation: The document is positive due to the securing of additional funding for a critical research program. The collaboration with reputable institutions further enhances the positive outlook.

Positives

• The additional $8 million in funding provides financial support for the second year of the ACT-EAP.
• The continued collaboration with Columbia University and Synapticure strengthens the program's scientific and clinical expertise.
• The funding demonstrates ongoing support from the NIH for Clene's ALS treatment program.
• The program is aligned with the Accelerating Access to Critical Therapies for ALS Act, highlighting its importance.

Risks

• Carryover of unspent funds from prior periods is not automatic and requires prior approval from Columbia University.
• The total amount of funds obligated may not reflect the actual balance available due to carryover restrictions.

Future Outlook

The funding supports the second year of the ACT-EAP, with continued research and development expected for the CNM-Au8 treatment of ALS.

Management Comments

• Robert Etherington, President and CEO of Clene Inc., signed the subaward amendment on behalf of the company.

Industry Context

This announcement highlights the ongoing efforts in the pharmaceutical industry to develop treatments for ALS, a debilitating neurodegenerative disease. The collaboration between a biotech company, a university, and a specialty clinic is a common model for advancing medical research.

Comparison to Industry Standards

• The NIH grant of $45.1 million over four years is a significant amount of funding for an ALS research program, indicating the importance of the project.
• The collaboration with Columbia University, a leading research institution, and Synapticure, a specialized neurology clinic, is a common approach in the industry to leverage expertise and resources.
• Expanded Access Programs are a standard pathway for providing experimental treatments to patients with serious diseases, such as ALS, when no other options are available.

Stakeholder Impact

• Shareholders will view the additional funding positively, as it supports the company's research and development efforts.
• Patients with ALS may benefit from the continued development of the CNM-Au8 treatment.
• Employees of Clene will continue to work on the ACT-EAP program.

Next Steps

• Clene will continue to execute the ACT-EAP for CNM-Au8 treatment of ALS.
• The company will track unobligated balances and seek carryover approvals from Columbia University as needed.

Key Dates

Keywords

ALS, Amyotrophic Lateral Sclerosis, CNM-Au8, NIH Grant, Expanded Access Program, Clene Inc., Columbia University, Synapticure, Funding, Subaward